⚡ Narrativ-Shift
FV revised from $39.50 to $46.00 driven by FDA-approved oral Wegovy pill (Dec 2025) launch at $149/month opening injection-averse patient cohort. Oral semaglutide reaches 50,000 Rx/week pace, providing patent-cliff buffer.
Chart & Einstieg
Forward Fair Value · Calculator
| Jahr | Claude FV | Deine FV | Δ FV | Revenue (Deine) | Margin (Deine) | Upside Claude | Upside Deine |
|---|---|---|---|---|---|---|---|
| Ende 2026 | $0.00 | $0.00 | — | $42B | +45.0% | -100.0% | -100.0% |
| Ende 2027 | $0.00 | $0.00 | — | $46B | +47.0% | -100.0% | -100.0% |
| Ende 2028 | $0.00 | $0.00 | — | $51B | +49.0% | -100.0% | -100.0% |
Historie (5 Jahre)
Begründung
These · aktualisiert 01.05.2026
Novo Nordisk has navigated a major de-rating (>50% from peak) and is now attractively valued at 11.7x P/E — the cheapest large-cap pharma relative to earnings quality. The December 2025 FDA approval of oral Wegovy (first-ever oral GLP-1 for obesity) at $149/month is a structural game-changer: it opens the ~50% of patients who refuse injections and creates a new patient funnel at dramatically lower price points. With 50,000 Rx/week within weeks of launch at 70,000+ pharmacies, the adoption curve is steeper than any prior GLP-1 launch. The 2026 guidance decline (-5% to -13% CER) represents a trough year; FY2027 begins the recovery driven by oral semaglutide scale, Amycretin/Zenagamtide Phase 3, and ex-US GLP-1 penetration still at early innings.
CagriSema's clinical miss removed Novo's most important next-gen asset protecting against the 2031/32 semaglutide patent cliff. Without a clearly superior successor molecule to tirzepatide, the post-cliff revenue decline could be steeper than current models assume. The January 2027 Wegovy/Ozempic 50% list price cut will compress 2027 US revenue by $5-8B, making the year-1 oral semaglutide revenue meaningful but insufficient to fully offset the pricing headwind. Eli Lilly's orforglipron (oral, once-daily, no food restrictions) in Phase 3 could erode oral Wegovy market share from 2027.
May 6, 2026: Q1 2026 earnings — first detailed oral Wegovy prescription data and US channel inventory update. H2 2026: Amycretin/Zenagamtide Phase 3 readouts — critical for patent-cliff hedge. January 2027: 50% Wegovy/Ozempic list price cut implementation — market reaction defines 2027 re-rating direction. Any positive CagriSema formulation rescue data would be strongly positive.
1) Oral Wegovy vs orforglipron competition: Lilly's oral GLP-1 in Phase 3 lacks the food-timing restriction of early semaglutide formulations — if approved with superior convenience, it could materially slow oral Wegovy adoption from 2027. 2) MFN pricing 2027: beyond the 50% list price cut, further executive order MFN application could reduce net pricing by another 20-30%, compressing the terminal value in the DCF. 3) Pipeline: Amycretin failure would leave Novo without a credible next-generation obesity molecule, making the post-2031 cliff the defining bear case.
Snapshot-History
| Datum | Preis | Market Cap | P/E | Rev TTM | Rev Growth | EBITDA-Marge |
|---|---|---|---|---|---|---|
| 01.05.2026 | $42.22 | $187.5B | 11.7 | $45.3B | +6.4% | +48.4% |
| 30.04.2026 | $40.29 | $179.1B | 11.2 | $45.3B | +6.4% | +48.4% |
News
- 28.04.2026Snap: 01.05.2026●●○Oral Semaglutide Shows Efficacy in Pediatric Type 2 Diabetes Trial — NVO Pipeline Expands
Novo Nordisk announced positive Phase III results for oral semaglutide in children and adolescents with Type 2 diabetes, expanding the addressable population beyond adults. This is the first oral GLP-1 to show efficacy in pediatric T2D, potentially adding a significant new patient segment to the oral semaglutide franchise.
Yahoo Finance - 01.05.2026●●●Novo Nordisk submits oral semaglutide 25mg for FDA review in obesity
FDA submission for oral semaglutide 25mg in obesity indication filed, with decision expected H2 2026. Oral formulation could expand addressable patient population significantly by removing injection barrier.
Novo Nordisk IR - 01.05.2026●●○Q1 2026 earnings scheduled May 6, 2026 — analyst consensus EPS ~$0.85-0.90
Q1 2026 results to be released May 6, 2026. Analysts watching for early signs of Wegovy HD adoption, US pricing impact, and any update to full-year guidance range.
MarketBeat - 29.04.2026Snap: 01.05.2026●●●Novo Nordisk Q1 2026 Earnings May 6: First Data on Oral Wegovy Ramp, MFN Impact
Novo Nordisk reports Q1 2026 on May 6 — first earnings with oral Wegovy commercial data after the December 2025 FDA approval and January 2026 $149/month launch. Key metrics: oral Wegovy prescription trajectory (reached 50,000 Rx/week by January 23), US channel inventory status, and updated MFN pricing guidance. Company guided FY2026 CER growth of -5% to -13%.
Yahoo Finance - 01.05.2026●●●Novo Nordisk 2026 guidance: Sales to decline 5-13% at constant exchange rates
NVO's 2026 guidance projects first revenue decline in GLP-1 era, driven by MFN pricing framework, Medicaid coverage cuts, and planned 50% list price reduction for Wegovy/Ozempic from January 2027. Stock fell 18% on the announcement.
Pharmaceutical Technology - 01.05.2026●●●CagriSema fails non-inferiority vs tirzepatide in REDEFINE 4 Phase 3 trial
CagriSema achieved 23% weight loss at 84 weeks but missed primary endpoint of non-inferiority vs Eli Lilly's tirzepatide. NVO fell 16%+ on February 23, removing the clearest pipeline catalyst for post-cliff revenue defense.
Capital.com / Novo Nordisk - 01.05.2026●●●Novo Nordisk launches Wegovy HD (semaglutide 7.2mg) in US at $399/month for cash patients
Wegovy HD launched April 7, 2026 at $399/month cash or $25/month with commercial coverage following March 2026 FDA approval. Higher dose targeting deeper weight loss to compete with tirzepatide.
Capital.com - 30.04.2026●●●U.S. Novo Nordisk GLP-1 sales forecast to decline 20% in 2026 on IRA pricing + Medicaid changes
Mehrere Analysten revidieren US-GLP-1-Prognosen nach unten: IRA-Preisverhandlungen für Ozempic ab 2026 und Medicaid-Kürzungen könnten US-Revenue um 15–20% drücken. Ex-US-Wachstum (Europa, Japan, EM) soll ~20% liefern.
Analyst Consensus / Seeking Alpha - 30.04.2026●●●CagriSema Phase 3 Trial Ergebnisse erwartet H2 2026 — nächster großer Pipeline-Catalyst
CagriSema (Cagrilintide + Semaglutid Kombination) zeigt in Phase-2-Daten +22.7% Gewichtsreduktion bei Adipositas. Phase-3-Leseout H2 2026 könnte bei Erfolg den Patent-Cliff-Hedge darstellen.
Novo Nordisk IR / nelhydrogen.com - 30.04.2026●●●Novo Nordisk 2025 Revenue +6.4% YoY auf DKK 309B — starke Verlangsamung von >20% Vorjahres-Wachstum
FY2025 Revenue DKK 309B (+6.4% YoY) und EBITDA-Marge 48.4%. Starke Wachstumsverlangsamung gegenüber FY2024 (+25%). FCF DKK 58.96B stabil, aber US-Segment unter Druck durch Medicaid-Coverage-Änderungen.
StockAnalysis / Yahoo Finance